Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (1-10 of 182) with videos related to

Pageof 19
Sort By:
Clinical Advances in Hematology & Oncology : H&O|January 31, 2024
Genomic risk stratification in chronic lymphocytic leukemiaAdrian Wiestner
Clinical Advances in Hematology & Oncology : H&O|April 10, 2015
Clinical use of BTK inhibitorsAdrian Wiestner
Cytometry. Part B, Clinical Cytometry|August 15, 2006
Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemiaAdrian Wiestner
The Lancet. Oncology|September 18, 2015
PROLONGing remissions in patients with CLLAdrian Wiestner
Blood|May 24, 2014
Predicting treatment outcomes in CLLAdrian Wiestner
Blood|August 10, 2012
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemiaAdrian Wiestner
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax - Doubling Down on CLLAdrian Wiestner
Haematologica|March 1, 2021
Validating genomic tools for precision medicine in chronic lymphocytic leukemia: ERIC leads the wayAdrian Wiestner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignanciesAdrian Wiestner
Clinical Advances in Hematology & Oncology : H&O|April 10, 2015
Clinical trial data on the BTK pathway in B-cell malignanciesAdrian Wiestner
Pageof 19

Showing results (1-10 of 182) with videos related to

Sort By:
Pageof 19
Clinical Advances in Hematology & Oncology : H&O|January 31, 2024
Genomic risk stratification in chronic lymphocytic leukemiaAdrian Wiestner
Clinical Advances in Hematology & Oncology : H&O|April 10, 2015
Clinical use of BTK inhibitorsAdrian Wiestner
Cytometry. Part B, Clinical Cytometry|August 15, 2006
Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemiaAdrian Wiestner
The Lancet. Oncology|September 18, 2015
PROLONGing remissions in patients with CLLAdrian Wiestner
Blood|May 24, 2014
Predicting treatment outcomes in CLLAdrian Wiestner
Blood|August 10, 2012
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemiaAdrian Wiestner
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax - Doubling Down on CLLAdrian Wiestner
Haematologica|March 1, 2021
Validating genomic tools for precision medicine in chronic lymphocytic leukemia: ERIC leads the wayAdrian Wiestner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignanciesAdrian Wiestner
Clinical Advances in Hematology & Oncology : H&O|April 10, 2015
Clinical trial data on the BTK pathway in B-cell malignanciesAdrian Wiestner
Pageof 19